Novartis Signs Cancer Drug Development Deal With Potential Value Exceeding $2 Billion
Key Facts
Taiwan’s OBI Pharma announced a collaboration and licensing agreement with Novartis Pharma AG to develop a new generation of antibody-drug conjugates, in a deal with a potential value exceeding $2 billion. The company said the consideration includes an upfront payment of $30 million, as well as payments tied to development milestones, regulatory approvals and commercial achievements. The total announced value is therefore contingent on those milestones, while the upfront payment is the amount specified at signing. OBI is also entitled to tiered royalties on net sales of licensed products arising from the collaboration. The agreement grants Novartis exclusive global rights in selected classes of undisclosed drug payloads.
The collaboration covers the use of OBI’s proprietary antibody-drug conjugate technologies, along with related patents and know-how. The licenses will focus on drug payload classes selected by Novartis that neither company named. Under the agreement, OBI will evaluate new linker approaches for connecting drug payloads to antibodies, using Novartis payloads. The agreement gives Novartis the option to expand the collaboration to additional classes of new payloads. The announcement does not specify whether or when the option will be exercised, while royalties are tied to net sales of products resulting from the collaboration.
Ya-Chi Chen, OBI’s acting chief executive, described the agreement as recognition of the scientific and commercial potential of the company’s technologies. He said: "This agreement recognizes the scientific and commercial potential of our proprietary technologies and reflects the value of our differentiated platform." Shiva Malik, Novartis’ head of oncology research, added that the collaboration supports the company’s efforts to develop new treatments. She said: "This collaboration supports our ambition to create new treatments and potentially expand therapeutic options for patients." The announcement thus links OBI’s antibody-drug conjugate design technologies with Novartis’ work on drug payload classes it has not disclosed.
The agreement comes amid other deals Novartis announced in cancer treatments during 2026. On July 6, the company announced an agreement to acquire Myricx Bio, saying the company was developing two lead assets targeting B7-H3 and HER2, and that its platform adds drug payloads for antibody-drug conjugates. Novartis said at the time that new payload mechanisms were needed to address resistance and broaden the impact of these treatments on patients. On October 29, EL7 reported a separate agreement between Novartis and Dren Bio that included an upfront payment of $150 million. That deal differs from the OBI agreement, which has a $30 million upfront payment and includes royalties and potential milestone payments.
OBI’s pipeline includes OBI-992, an antibody-drug conjugate targeting TROP2 that is in Phase 1 trials for advanced solid tumors. The company said it is continuing to collect and analyze clinical data to assess safety, pharmacokinetics and preliminary efficacy. It also said its Phase 1/2 study of OBI-902 is enrolling participants in the United States and Taiwan to assess the same measures. These programs provide context for the company’s clinical work in the field, but remain separate from the new agreement with Novartis. The announcement did not specify a timeline for developing drugs from the collaboration or beginning clinical testing.
In trading, Novartis shares closed at $160.5 on November 13, 2026, the day the agreement was announced, compared with $160.25 on November 12 and $160.32 on November 11, according to EL7 data. The announcement did not detail the collaboration’s expected financial impact on the company’s results or the timing of any potential revenue from licensed products. Novartis reported net debt of $37.4 billion on September 30, 2026, compared with $21.9 billion on December 31, 2025, attributing the increase mainly to acquisition-related cash outflows and other factors. The company also forecast low-single-digit growth in net sales for 2026, with core operating income expected to remain stable or grow at the same low rate. The OBI announcement does not specify when the companies may report further development results or exercise the expansion option.